Activation of type II cannabinoid receptors as variant for mesenchymal stem cell potentiation in a model of peripheral neuropathic pain
-
Published:2023-08-28
Issue:2
Volume:
Page:29-39
-
ISSN:2074-2088
-
Container-title:Medical and Biological Problems of Life Activity
-
language:
-
Short-container-title:jour
Author:
Yerofeyeva A.-M.ORCID, Pinchuk S.ORCID, Ryabceva S.ORCID, Molchanova A.ORCID
Abstract
Transplantation of adipose-derived mesenchymal stem cells (ADMSCs) is currently considered as one of the treatment methods of peripheral neuropathic pain. The analgesic effect of ADMSCs has been proven, and one of the potential options for its enhancement and prolongation could be the activation of type 2 cannabinoid receptors (CB2 receptors). The antinociceptive and reparative effects of ADMSCs were analyzed after type 2 cannabinoid receptors (CB2) pharmacological stimulation by the selective agonist AM1241 on the ADMSC’s membranes and in the tissues of the area of sciatic nerve traumatic injury in rats. It was found that pharmacological stimulation of CB2 receptors on ADMSC’s membranes accelerated the recovery of nociceptive sensitivity to mechanical and thermal stimuli compared with transplantation of ADMSCs alone. Early (before transplantation of ADMSCs) activation of CB2 receptors in tissues surrounding the sciatic nerve more effectively attenuated nociceptive responses to thermal stimuli in the long-term period of the experiment. Stimulation of CB2 receptors did not significantly affect the rate of recovery of gait parameters in rats after ADMSCs transplantation, but led to the structure recovery of the sciatic nerve distal segment of rats. The latter was expressed in increased proliferation of Schwann cells and a decrease in the number of damaged nerve fibers.
Publisher
Republican Scientific and Practical Center for Radiation Medicine and Human Ecology
Reference11 articles.
1. Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris), 2019, vol. 175 no. 1-2, pp. 16-25. https://doi.org/10.1016/j.neurol.2018.09.016 2. Scholz J., Finnerup N.B., Attal N., Aziz Q., Baron R., Bennett M.I., Benoliel R., Cohen M,. Cruccu G., Davis K.D., Evers S., First M., Giamberardino M.A., Hansson P., Kaasa S., Korwisi B., Kosek E., Lavand'homme P., Nicholas M., Nurmikko T., Perrot S., Raja S.N., Rice A.S.C., Rowbotham M.C., Schug S., Simpson D.M., Smith B.H., Svensson P., Vlaeyen J.W.S., Wang S.J., Barke A., Rief W., Treede R.D. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain, 2019, vol. 160, no. 1, pp. 53-59. https://doi.org/10.1097/j.pain.0000000000001365 3. Cavalli E., Mammana S., Nicoletti F., Bramanti P., Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol, 2019, vol. 33, no. 2058738419838383. https://doi.org/10.1177/2058738419838383 4. Yerofeyeva A.M.V., Molchanova A.Yu. Impact of adipose-derived allogeneic mesenchymal stem cell transplantation on nociceptive reactions and gait parameters in rats with experimental peripheral neuropathy [Vliyanie transplantacii allogennyh mezenhimal'nyh stvolovyh kletok zhirovoj tkani na nociceptivnye reakcii i parametry pohodki krys s eksperimental'noj perifericheskoj nejropatiej]. Proceedings of the National Academy of Sciences of Belarus, Medical series (Vescі Nacyyanal'naj akademіі navuk Belarusі. Seryya medycynskіh navuk.), 2022, vol. 19, no. 4, pp. 404-412. https://doi.org/10.29235/1561-8323-2020-64-5-574-582 (in Russ.) 5. Erofeeva, A.M.V. The impact of pharmacological blocking of type 1 cannabinoid receptors on the effectiveness of mesenchymal stem cell transplantation in experimental peripheral neuropathy [Vliyanie farmakologicheskoj blokady kannabinoidnyh receptorov 1 tipa na effektivnost' transplantacii mezenhimal'nyh stvolovyh kletok pri eksperimental'noj perifericheskoj nejropatii]. Vitebsk Medical Journal (Vestnik VGMU), 2022, vol. 21, no. 6, pp. 46-57. https://doi.org/10.22263/2312-4156.2022.6.47 (in Russ.)
|
|